Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Uveal Melanoma × Crizotinib × Clear all

Phase

Phase 2/3 1 Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uveal Melanoma 1 Melanoma 1 Granuloma, Plasma Cell 1

Interventions

Nivolumab 2 Ipilimumab 2 salicylhydroxamic acid 1 pembrolizumab 1 Triamcinolone Acetonide 1 Ranibizumab 1 Dacarbazine 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

IDEAYA Biosciences

Phase 2/3 Active not recruiting

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡